Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
To determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA)...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-09-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X16301322 |
| _version_ | 1818586185366241280 |
|---|---|
| author | Yuan-Chi Shen Po-Hui Chiang Hao-Lun Luo Yao-Chi Chuang Yen-Ta Chen Chih-Hsiung Kang Chun-Chien Hsu Wei-Ching Lee Yuan-Tso Cheng |
| author_facet | Yuan-Chi Shen Po-Hui Chiang Hao-Lun Luo Yao-Chi Chuang Yen-Ta Chen Chih-Hsiung Kang Chun-Chien Hsu Wei-Ching Lee Yuan-Tso Cheng |
| author_sort | Yuan-Chi Shen |
| collection | DOAJ |
| description | To determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA) response, and adverse events. The study included 33 patients receiving ≤ 10 cycles of docetaxel and 40 patients receiving > 10 cycles. Patients receiving > 10 cycles were younger than those who received ≤ 10 cycles. There was no statistical significant difference in overall survival between the two groups (log-rank test, p = 0.75). Adverse effects were more common among patients receiving ≥ 10 cycles of treatment. A PSA flare-up was observed among six patients (8.2%); the median duration of the PSA surge was 3 weeks (range, 3–12 weeks). The overall survival rates in patients with PSA flare-up were comparable with the patients having PSA response. We concluded that at least four cycles of docetaxel should be administered in metastatic castration-resistant prostate cancer patients in order not to cease treatment prematurely from potentially beneficial chemotherapy. However, administering > 10 cycles does not result in any further improvement in survival and is associated with more adverse effects. |
| first_indexed | 2024-12-16T08:48:57Z |
| format | Article |
| id | doaj.art-5d599794700c45d98b8bccf636f7620e |
| institution | Directory Open Access Journal |
| issn | 1607-551X |
| language | English |
| last_indexed | 2024-12-16T08:48:57Z |
| publishDate | 2016-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Kaohsiung Journal of Medical Sciences |
| spelling | doaj.art-5d599794700c45d98b8bccf636f7620e2022-12-21T22:37:30ZengWileyKaohsiung Journal of Medical Sciences1607-551X2016-09-0132945846310.1016/j.kjms.2016.07.012Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancerYuan-Chi ShenPo-Hui ChiangHao-Lun LuoYao-Chi ChuangYen-Ta ChenChih-Hsiung KangChun-Chien HsuWei-Ching LeeYuan-Tso ChengTo determine the optimal number of cycles of docetaxel for metastatic castration-resistant prostate cancer, we retrospectively collected 73 patients receiving varying numbers of docetaxel plus prednisolone and analyzed the clinical outcomes including overall survival, prostate-specific antigen (PSA) response, and adverse events. The study included 33 patients receiving ≤ 10 cycles of docetaxel and 40 patients receiving > 10 cycles. Patients receiving > 10 cycles were younger than those who received ≤ 10 cycles. There was no statistical significant difference in overall survival between the two groups (log-rank test, p = 0.75). Adverse effects were more common among patients receiving ≥ 10 cycles of treatment. A PSA flare-up was observed among six patients (8.2%); the median duration of the PSA surge was 3 weeks (range, 3–12 weeks). The overall survival rates in patients with PSA flare-up were comparable with the patients having PSA response. We concluded that at least four cycles of docetaxel should be administered in metastatic castration-resistant prostate cancer patients in order not to cease treatment prematurely from potentially beneficial chemotherapy. However, administering > 10 cycles does not result in any further improvement in survival and is associated with more adverse effects.http://www.sciencedirect.com/science/article/pii/S1607551X16301322ChemotherapyDocetaxelFlare-up phenomenonMetastatic castration resistant prostate cancer |
| spellingShingle | Yuan-Chi Shen Po-Hui Chiang Hao-Lun Luo Yao-Chi Chuang Yen-Ta Chen Chih-Hsiung Kang Chun-Chien Hsu Wei-Ching Lee Yuan-Tso Cheng Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer Kaohsiung Journal of Medical Sciences Chemotherapy Docetaxel Flare-up phenomenon Metastatic castration resistant prostate cancer |
| title | Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer |
| title_full | Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer |
| title_fullStr | Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer |
| title_full_unstemmed | Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer |
| title_short | Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer |
| title_sort | determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration resistant prostate cancer |
| topic | Chemotherapy Docetaxel Flare-up phenomenon Metastatic castration resistant prostate cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1607551X16301322 |
| work_keys_str_mv | AT yuanchishen determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT pohuichiang determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT haolunluo determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT yaochichuang determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT yentachen determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT chihhsiungkang determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT chunchienhsu determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT weichinglee determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer AT yuantsocheng determineoftheoptimalnumberofcyclesofdocetaxelinthetreatmentofmetastaticcastrationresistantprostatecancer |